186 related articles for article (PubMed ID: 30512122)
1. Adverse Events in the Efficacy of Crotalidae Polyvalent Immune Fab Antivenom vs Placebo in Recovery from Copperhead Snakebite Trial.
Mullins ME; Gerardo CJ; Bush SP; Rose SR; Greene S; Quackenbush EB; Lewis B; Anderson VE; Kleinschmidt KC; Schwarz RB; Charlton NP; Toschlog EA; Sharma K; Denning DA; Lavonas EJ
South Med J; 2018 Dec; 111(12):716-720. PubMed ID: 30512122
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional Rescue Therapy on Recovery From Copperhead Snake Envenomation: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial.
Gerardo CJ; Quackenbush E; Lewis B; Rose SR; Greene S; Toschlog EA; Charlton NP; Mullins ME; Schwartz R; Denning D; Sharma K; Kleinschmidt K; Bush SP; Ryan S; Gasior M; Anderson VE; Lavonas EJ
Ann Emerg Med; 2017 Aug; 70(2):233-244.e3. PubMed ID: 28601268
[TBL] [Abstract][Full Text] [Related]
3. Initial experience with Crotalidae polyvalent immune Fab (ovine) antivenom in the treatment of copperhead snakebite.
Lavonas EJ; Gerardo CJ; O'Malley G; Arnold TC; Bush SP; Banner W; Steffens M; Kerns WP
Ann Emerg Med; 2004 Feb; 43(2):200-6. PubMed ID: 14747809
[TBL] [Abstract][Full Text] [Related]
4. Incidence of allergic reactions to Crotalidae polyvalent immune Fab.
Khobrani M; Huckleberry Y; Boesen KJ; Aljabri A; Alharthi M; Patanwala AE
Clin Toxicol (Phila); 2019 Mar; 57(3):164-167. PubMed ID: 30260274
[TBL] [Abstract][Full Text] [Related]
5. Recovery from Copperhead Snake Envenomation: Role of Age, Sex, Bite Location, Severity, and Treatment.
Lavonas EJ; Burnham RI; Schwarz J; Quackenbush E; Lewis B; Rose SR; Greene S; Toschlog EA; Charlton NP; Mullins ME; Schwartz R; Denning D; Sharma K; Kleinschmidt K; Bush SP; Anderson VE; Ginde AA; Gerardo CJ
J Med Toxicol; 2020 Jan; 16(1):17-23. PubMed ID: 31482319
[TBL] [Abstract][Full Text] [Related]
6. Severe adverse drug reaction following Crotalidae Polyvalent Immune Fab (Ovine) administration for copperhead snakebite.
Lepak MR; Bochenek SH; Bush SP
Ann Pharmacother; 2015 Jan; 49(1):145-9. PubMed ID: 25341425
[TBL] [Abstract][Full Text] [Related]
7. Ethical considerations in design of a study to evaluate a US Food and Drug Administration-approved indication: antivenom versus placebo for copperhead envenomation.
Gerardo CJ; Lavonas EJ; McKinney RE
Clin Trials; 2014 Oct; 11(5):560-4. PubMed ID: 25055811
[TBL] [Abstract][Full Text] [Related]
8. Predictors of FabAV use in copperhead envenomation.
Ramirez-Cueva F; Larsen A; Knowlton E; Baab K; Rainey Kiehl R; Hendrix A; Condren M; Woslager M
Clin Toxicol (Phila); 2022 May; 60(5):609-614. PubMed ID: 34989644
[TBL] [Abstract][Full Text] [Related]
9. Acute hypersensitivity reaction to Crotalidae polyvalent immune Fab (CroFab) as initial presentation of galactose-α-1,3-galactose (α-gal) allergy.
Rizer J; Brill K; Charlton N; King J
Clin Toxicol (Phila); 2017 Aug; 55(7):668-669. PubMed ID: 28443380
[TBL] [Abstract][Full Text] [Related]
10. Acute adverse events associated with the administration of Crotalidae polyvalent immune Fab antivenom within the North American Snakebite Registry.
Kleinschmidt K; Ruha AM; Campleman S; Brent J; Wax P;
Clin Toxicol (Phila); 2018 Nov; 56(11):1115-1120. PubMed ID: 29688079
[No Abstract] [Full Text] [Related]
11. Control of venom-induced tissue injury in copperhead snakebite patients: a post hoc sub-group analysis of a clinical trial comparing F(ab')
Gerardo CJ; Keyler DE; Rapp-Olson M; Dart RC
Clin Toxicol (Phila); 2022 Apr; 60(4):521-523. PubMed ID: 34590543
[TBL] [Abstract][Full Text] [Related]
12. Coagulation parameters in copperhead compared to other Crotalinae envenomation: secondary analysis of the F(ab')
Gerardo CJ; Vissoci JR; Brown MW; Bush SP
Clin Toxicol (Phila); 2017 Feb; 55(2):109-114. PubMed ID: 27806644
[TBL] [Abstract][Full Text] [Related]
13. Early administration of Fab antivenom resulted in faster limb recovery in copperhead snake envenomation patients.
Anderson VE; Gerardo CJ; Rapp-Olsson M; Bush SP; Mullins ME; Greene S; Toschlog EA; Quackenbush E; Rose SR; Schwartz RB; Charlton NP; Lewis B; Kleinschmidt KC; Sharma K; Lavonas EJ
Clin Toxicol (Phila); 2019 Jan; 57(1):25-30. PubMed ID: 30175628
[TBL] [Abstract][Full Text] [Related]
14. Late hemotoxicity following North American rattlesnake envenomation treated with crotalidae immune F(ab')
Spyres MB; Padilla GK; Gerkin RD; Hoyte CO; Wolk BJ; Ruha AM;
Clin Toxicol (Phila); 2022 Jul; 60(7):838-842. PubMed ID: 35261320
[TBL] [Abstract][Full Text] [Related]
15. Incidence of immediate hypersensitivity reaction and serum sickness following administration of Crotalidae polyvalent immune Fab antivenom: a meta-analysis.
Schaeffer TH; Khatri V; Reifler LM; Lavonas EJ
Acad Emerg Med; 2012 Feb; 19(2):121-31. PubMed ID: 22320362
[TBL] [Abstract][Full Text] [Related]
16. Antivenom Treatment Is Associated with Fewer Patients using Opioids after Copperhead Envenomation.
Freiermuth CE; Lavonas EJ; Anderson VE; Kleinschmidt KC; Sharma K; Rapp-Olsson M; Gerardo C;
West J Emerg Med; 2019 May; 20(3):497-505. PubMed ID: 31123552
[TBL] [Abstract][Full Text] [Related]
17. Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune Fab antivenom.
Cannon R; Ruha AM; Kashani J
Ann Emerg Med; 2008 Apr; 51(4):407-11. PubMed ID: 18191286
[TBL] [Abstract][Full Text] [Related]
18. Continuous IV Crotalidae Polyvalent Immune Fab (Ovine) (FabAV) for selected North American rattlesnake bite patients.
Bush SP; Seifert SA; Oakes J; Smith SD; Phan TH; Pearl SR; Reibling ET
Toxicon; 2013 Jul; 69():29-37. PubMed ID: 23474267
[TBL] [Abstract][Full Text] [Related]
19. Crotalidae polyvalent immune Fab: in patients with North American crotaline envenomation.
Keating GM
BioDrugs; 2011 Apr; 25(2):69-76. PubMed ID: 21443271
[TBL] [Abstract][Full Text] [Related]
20. Safety and cost-effectiveness of a clinical protocol implemented to standardize the use of Crotalidae polyvalent immune Fab antivenom at an academic medical center.
Weant KA; Bowers RC; Reed J; Braun KA; Dodd DM; Baker SN
Pharmacotherapy; 2012 May; 32(5):433-40. PubMed ID: 22467377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
